Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1425.80p Bid 1425.20p Ask 1425.80p Change 1.89%
Last Updated: 19/08/2022 23:24. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

UK-based GSK Plc is one of the world's leading pharmaceutical research companies. The company was created out of the merger between GlaxoWellcome and SmithKline Beecham in 2000.

Financial Highlights Year Ended 31/12/2021

Revenue
£34,114.00m
Operating Profit/Loss
£6,201.00m
Dividend yield (%)
4.00
Total dividend for year
n/ap
Dividend cover
1.42
P/E Ratio
17.70

Key Personnel

Ms Emma Walmsley
Chief Executive Officer
Mr Iain Mackay
Chief Financial Officer
Mr Hal Barron
Chief Scientific Officer
Dr Jesse Goodman
Independent Non-Executive Director
Dr Laurie Glimcher
Independent Non-Executive Director
Mr Harry (Hal) C. Dietz
Independent Non-Executive Director
Mr Urs Rohner
Independent Non-Executive Director
Mr Vishal Sikka
Independent Non-Executive Director
Mr Jonathan Symonds
Non-Executive Chairman
Dr Anne Beal
Non-Executive Director
Mr Charles Bancroft
Non-Executive Director

Stock Details

EPIC
GSKL
ISIN
GB0009252882
Shares in Issue
4,870.09m
Market cap
£69,437.74m

Analyst Views (7)

Strong Buy
 
0%
Buy
 
28.57%
Hold
 
57.14%
Sell
 
14.29%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1,425.80p
Bid Price
1,425.20p
Ask Price
1,425.80p
Volume
1,939,830
Change Today
26.40p
% Change Today
1.89%
Open
1,409.20p
Previous Close
1,425.80p
Intraday High
1,437.40p
Intraday Low
1,401.00p
52 Week High
2,258.50p
52 Week Low
1,399.40p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

News

GSK application for myelofibrosis drug accepted by US FDA 17/08/2022 07:54:33 Plaintiff in GSK Zantac lawsuit pulls suit for now 17/08/2022 07:37:14 GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims 12/08/2022 07:26:54 GSK, Haleon, Sanofi slump amid Zantac litigation woes 11/08/2022 12:35:19 GSK lifts full-year outlook as Q2 sales rise 27/07/2022 07:21:38 Citi starts GSK spinoff Haleon at 'buy' 21/07/2022 07:26:34 GSK spins off consumer healthcare giant Haleon 18/07/2022 12:12:44 GSK submits shingles vaccine application in Japan for over 18s 28/06/2022 07:25:58 GlaxoSmithKline to invest £1bn in infectious disease R&D 23/06/2022 14:18:08 GSK says respiratory vaccine shows 'significant' efficacy in trial 10/06/2022 07:03:43 GSK's MMR vaccine Priorix gets US FDA approval 06/06/2022 07:57:32 GlaxoSmithKline to acquire US biopharmaceutical firm Affinivax 31/05/2022 07:06:13 GlaxoSmithKline nears deal to build £400m science campus in Hertfordshire 30/05/2022 08:30:43 China approves two-dose schedule for GSK's cervical cancer drug 27/05/2022 07:02:45 GSK sales top forecasts 27/04/2022 08:54:55 US FDA accepts GSK application for kidney disease drug 19/04/2022 07:31:46 GSK agrees to buy Sierra Oncology for $1.9bn 13/04/2022 07:17:23 GSK's Cabenuva receives approved label update from FDA 24/03/2022 15:06:40 EU accepts GSK marketing application for kidney treatment 01/03/2022 07:01:31 GSK to spin off consumer healthcare unit in July 28/02/2022 11:37:20 Glaxo halts trial of respiratory virus maternal vaccine candidate 28/02/2022 07:50:16 GSK and Sanofi seek approval for Covid-19 jab 23/02/2022 11:23:47 Glaxo pauses enrolment and vaccination in RSV vaccine candidate trials 18/02/2022 07:37:42 Glaxo's Benlysta lupus treatment approved in China for adults 10/02/2022 09:42:18 GSK Covid sales soar but sees slowdown next year 09/02/2022 08:29:47

Income Statement

Year End Date
31 Dec 2021
31 Dec 2020
 
£ (M)
£ (M)
Continuing Operations
Revenue
34,114.00
34,099.00
Operating Profit/Loss
6,201.00
7,783.00
Net Interest
-756.00
-848.00
Pre-Tax Profit
5,442.00
6,968.00
Profit After Tax from continuing operations
5,096.00
6,388.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
5,096.00
6,388.00
Attributable to:
Equity Holders of Parent Company
5,096.00
6,388.00
Minority Interests
n/a
639.00
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2021
31 Dec 2020
Basic
87.60p
1.17p
Diluted
86.60p
1.15p
Adjusted
113.20p
1.17p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2021
31 Dec 2020
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
10,672.00
11,006.00
Intangible Assets
40,631.00
40,421.00
Investment Properties
n/a
n/a
Investments
2,214.00
3,424.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
6,912.00
5,333.00
Current Assets
Inventories
5,783.00
5,996.00
Trade & Other Receivables
7,860.00
6,952.00
Cash at Bank & In Hand
4,274.00
6,292.00
Current Asset Investments
n/a
n/a
Other Current Assets
757.00
1,007.00
Other Assets
n/a
n/a
Total Assets
79,103.00
80,431.00

Liabilities

Year End Date
31 Dec 2021
31 Dec 2020
 
£ (M)
£ (M)
Current Liabilities
Borrowings
3,601.00
3,725.00
Other Current Liabilities
20,069.00
18,423.00
Total Current Liabilities
23,670.00
22,148.00
Non-Current Liabilities
Borrowings
20,572.00
23,425.00
Provisions
4,186.00
4,307.00
Other Non-Current Liabilities
9,333.00
9,743.00
Total Non-Current Liabilities
34,091.00
37,475.00
Other Liabilities
n/a
n/a
Total Liabilities
57,761.00
59,623.00

Net Assets

Year End Date
31 Dec 2021
31 Dec 2020
 
£ (M)
£ (M)
Net Assets
21,342.00
20,808.00

Capital & Reserves

Year End Date
31 Dec 2021
31 Dec 2020
 
£ (M)
£ (M)
Share Capital
1,347.00
1,346.00
Share Premium Account
3,301.00
3,281.00
Other Reserves
7,944.00
6,755.00
Retained Earnings
2,463.00
3,205.00
Shareholders Funds
15,055.00
14,587.00
Minority Interests/Other Equity
6,287.00
6,221.00
Total Equity
21,342.00
20,808.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
Q2
18 Aug 2022
06 Oct 2022
16.25p
Q1
19 May 2022
01 Jul 2022
14.00p
Q4
24 Feb 2022
07 Apr 2022
23.00p
Q3
18 Nov 2021
13 Jan 2022
19.00p
Q2
19 Aug 2021
07 Oct 2021
19.00p
Q1
20 May 2021
08 Jul 2021
19.00p
Q4
18 Feb 2021
08 Apr 2021
23.00p
Q3
12 Nov 2020
14 Jan 2021
19.00p
Q2
13 Aug 2020
08 Oct 2020
19.00p
Q1
14 May 2020
09 Jul 2020
19.00p
Q4
20 Feb 2020
09 Apr 2020
23.00p
Q3
14 Nov 2019
09 Jan 2020
19.00p
Q2
08 Aug 2019
10 Oct 2019
19.00p
Q1
16 May 2019
11 Jul 2019
19.00p
Q4
21 Feb 2019
11 Apr 2019
23.00p
Q3
15 Nov 2018
10 Jan 2019
19.00p
Q2
09 Aug 2018
11 Oct 2018
19.00p
Q1
10 May 2018
12 Jul 2018
19.00p
Q4
22 Feb 2018
12 Apr 2018
23.00p
Q3
09 Nov 2017
11 Jan 2018
19.00p
Q2
10 Aug 2017
12 Oct 2017
19.00p
Q1
11 May 2017
13 Jul 2017
19.00p
Q4
23 Feb 2017
13 Apr 2017
23.00p
Q3
03 Nov 2016
12 Jan 2017
19.00p
Q2
11 Aug 2016
13 Oct 2016
19.00p
Q1
12 May 2016
14 Jul 2016
19.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Q4
18 Feb 2016
14 Apr 2016
23.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Special
18 Feb 2016
14 Apr 2016
20.00p
Q3
12 Nov 2015
14 Jan 2016
19.00p
Q2
13 Aug 2015
01 Oct 2015
19.00p
Q1
14 May 2015
09 Jul 2015
19.00p

Dividend Metrics

Year End Date
31 Dec 2021
31 Dec 2020
Dividend growth
9,806.85%
-98.99%
Dividend yield
4.00%
n/a%
Dividend cover
1.42
1.45


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.